A. Andre

The Effect of Hepatic Insufficiency on the Safety and Pharmacokinetics of Paricalcitol (Zemplar®)

M. Chojkier, L. Williams, C. Locke, 2006, Nephron Clinical Practice.

Atrasentan, a n E ndothelin-Recep tor A ntagonist f or Refractory A denocarcinomas: S afety a nd P harmacokinetics

J. Nelson, M. Carducci, R. Donehower, 2013 .

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

M. Ratain, E. Vokes, C. Ryan, 2004, Clinical Cancer Research.

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.

J. Nelson, M. Carducci, R. Donehower, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics (PK) of the angiogenesis inhibitor ABT-510 in healthy subjects.

R. Humerickhouse, K. Marsh, C. Karyekar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.